Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 18 May 2020, 12:33 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
The first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes

TOKYO, May 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020 at pharmacies and drugstores throughout Japan, as a new addition to the Selbelle brand lineup of products which protect and condition the weakened stomach with a gastric mucus barrier.

SEI-I*, which is the value offered by the Selbelle brand, is Eisai's unique concept of increasing gastric mucus to protect the stomach wall while revitalizing the stomach to improve its condition. Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis. These ailments are thought to be caused by a decrease of mucus in the stomach and stagnation of stomach function that occur with aging.
For the first time in an OTC product, the in-house developed gastric mucus-increasing component 'teprenone' is contained in New Selbelle Premium at the same amount as found in prescription drugs.

The compounding amount of 'teprenone' was increased to 150mg / day for New Selbelle Premium from 112.5 mg / day for the conventional product. In addition, New Selbelle Premium contains two natural extracts that revitalize stomach functions and digestive enzymes that help to digest fat. The effect of SEI-I derived from these ingredients relieves stomach discomfort and restores the joy of eating by energizing the stomach.

As we enter the era of 100 years of life, Eisai considers it very important for all consumers to be able to enjoy their food every day in order to gain contentment in everyday life. With its launch of New Selbelle Premium, Eisai will evoke the joy of eating with the effects of SEI-I, and further respond to the wishes of consumers who want to enjoy their favorite foods through their whole lifetime and to enjoy their meals with precious family and friends.

* SEI-I, which is a registered trademark of Eisai (Registration number: 4983286), implies the idea of reconditioning the declined stomach function to normal.


Contact:
Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 15, 2025 09:03 HKT/SGT
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 7, 2025 08:14 HKT/SGT
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: